Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNF
Navigation
Daily News
- University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer’s disease
- BeaconEquity.com announces investment report featuring NexMed
- Panel Questions "VBAC Bans," Advocates Expanded Delivery Options for Women
- Scientists Solve Puzzle Of Chickens That Are Half Male And Half Female
- Sequencing Genome Of Entire Family Reveals Parents Give Kids Fewer Gene Mutations Than Was Thought
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||